Basal-bolus Insulin Therapy Versus Standard Therapy for the Inpatient Management of Type 2 Diabetes: the IDA2 Study

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

Also called NCT03244241

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as a collaborator
Registry
  • NCT NCT03244241
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Denmark (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT03244241. Randomized; no masking; primary purpose treatment. Start 2017-04-01 (actual); primary completion 2018-04-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Basal-bolus Insulin Therapy Versus Standard Therapy for the Inpatient Management of Type 2 Diabetes: the IDA2 Study
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Insulin Degludec 100 UNT/ML [Tresiba]
Lead sponsor
Merete Bechmann Christensen (class: other)
Collaborator
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct03244241
Content hash
01b215b209e2fd34db837cb64931c0ccca93457f07d6978fe9ebfb00fdfe3800